title: [Efficacy of intravitreal injections of ranibizumab compared to visudyne phototherapy in myopic choroidal neovascularization associated with high myopia].
abstract: BACKGROUND
  Myopic choroidal neovascularization (CNV) is the first cause of CNV in young patients. The aim of this study was to compare the efficacy of intravitreal injections (IVT) of ranibizumab with photodynamic therapy (PDT) in this indication.
  
  
  METHODS
  Retrospective comparative study analyzing the visual acuity (VA) outcomes of CNV myopic patients treated with either IVT or PDT.
  
  
  RESULTS
  Twenty-seven eyes of 25 patients were treated with PDT (group 1) and 18 eyes of 17 patients were treated with IVT of ranibizumab (group 2). Demographic data were similar in the two groups. The median initial VA was 20/80 for group 1 and 20/160 for group 2 (P=0.37). At 1 year, the median VA was 20/80 for group 1 (P=0.32) and 20/63 for group 2 (P=0.04). A significant improvement in VA was observed in 23.1% and in 27.3% of cases in groups 1 and 2, respectively (P=0.53). A significant VA worsening was observed in 34.6% of cases in group 1 and in 9.1% of cases in group 2 (P=0.21).
  
  
  CONCLUSIONS
  IVT of ranibizumab compared to PDT treatment showed greater efficacy in this study.
authors.affiliation: Département d'ophtalmologie, centre hospitalier intercommunal de Créteil, 40, avenue de Verdun, 94000 Créteil, France.
authors.forename: G
authors.initials: G
authors.lastname: Dethorey
authors.forename: N
authors.initials: N
authors.lastname: Leveziel
authors.forename: F
authors.initials: F
authors.lastname: Lalloum
authors.forename: R
authors.initials: R
authors.lastname: Forte
authors.forename: B
authors.initials: B
authors.lastname: Guigui
authors.forename: G
authors.initials: G
authors.lastname: Querques
authors.forename: A
authors.initials: A
authors.lastname: Glacet-Bernard
authors.forename: G
authors.initials: G
authors.lastname: Soubrane
authors.forename: H É
authors.initials: HÉ
authors.lastname: Souied
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000009:adverse effects; D010789:Phototherapy / Q000379:methods; D011166:Porphyrins / Q000008:administration & dosage* / Q000009:adverse effects; D000069579:Ranibizumab; D012189:Retrospective Studies; D016896:Treatment Outcome; D000077362:Verteporfin
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D000069579:Ranibizumab